AstraZeneca faces $198m bill for Seroquel litigation in US
Tuesday 10 August 2010
AstraZeneca tried to draw a line under the growing number of claims against its blockbuster anti-psychotic drug Seroquel yesterday when it paid out $198m (£124m) to claimants in the United States.
The agreement, which settles 17,500 claims against the Anglo-Swedish pharmaceuticals company, comes after patients complained they were not made aware of the risks associated with taking the drug – specifically that it could lead to diabetes. AstraZeneca has maintained that it has been open about the risks, adding yesterday that the only trial to consider the complaint found in its favour. The terms of the mediated deal are confidential.
Yesterday's agreement does not end the firm's litigation over Seroquel. As part of the deal, 2,900 claims have been dismissed, but as of 29 June Astra-Zeneca was defending 10,363 lawsuits involving 22,412 American plaintiffs.
The settlement also comes on top of the $520m (£327m) the company paid to the US Justice Department earlier this year to settle other cases relating to the marketing of Seroquel.
As part of its second-quarter results, published two weeks ago, AstraZeneca said it had reached an agreement with 4,000 claimants but because the amount of money was not material at the time, it was not obliged to release further details. In a statement yesterday, the company said the provision would be disregarded in calculating so-called core earnings and would therefore not affect the City's full-year earnings guidance.
"While the terms remain confidential and are subject to non-monetary agreements, we believe it was in the best interest of the company to explore resolving these cases through the mediation process," said a spokeswoman. "We remain committed to a strong defence effort, but will also continue to participate in good faith in court- ordered mediation."
The market welcomed the settlement, with AstraZeneca's shares gaining 1.54 per cent yesterday. Analysts described the announcement as "a modest but welcome development".
The settlement comes a month after rival GlaxoSmithKline said it was setting aside a record £1.57bn to settle claims relating to its diabetes drug Avandia. The deal effectively wiped out GSK's second-quarter earnings.
Diving in at the deep end is no excuse for shirking the style stakes
- 2 PornHub begs users to stop uploading video clips of Brazil getting beaten 7-1
- 3 Why I'm on the brink of burning my Israeli passport
- 4 L'Oreal cuts ties with Belgium supporter Axelle Despiegelaere after hunting trip photographs
- 5 The true Gaza back-story that the Israelis aren’t telling this week
Game of Thrones author George RR Martin says 'f*** you' to fans who fear he will die before finishing Westeros saga
Loom bands: Bids for dress made from colourful rubber pass £170,000 on eBay
Supermoon 2014: When and why will the moon look bigger and brighter this summer?
Gaza-Israel conflict: The terrible price Palestinian children are paying for Israel’s war with Hamas
Rotten egg smell could help battle heart disease and Alzheimer's
Sustained immigration has not harmed Britons' employment, say government advisers
War is war: Why I stand with Israel
7/7 memorial defaced on anniversary of 2005 attacks with ‘Blair lied thousands died’ graffiti
Australia facing international condemnation after turning around Sri Lankans at sea
Even when it brutalises one of its own teenage citizens, America is helpless against Israel
Socialist Worker called to apologise over ‘vile’ article saying Eton schoolboy Horatio Chapple's death is ‘reason to save the polar bears’
iJobs Money & Business
£70000 per annum: Harrington Starr: Information Security Manager (ISO 27001, A...
£75000 - £85000 per annum + ex bens: Deerfoot IT Resources Limited: Biztalk Te...
£60000 per annum: Harrington Starr: Trade Desk Specialist (FIX, Linux, Windows...
£35000 per annum: Harrington Starr: Service Desk Analyst (Windows, Active Dire...